Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00067834
Other study ID # N01AR32267
Secondary ID NIAMS-091
Status Completed
Phase Phase 1/Phase 2
First received August 28, 2003
Last updated December 22, 2015
Start date November 2003
Est. completion date October 2006

Study information

Verified date December 2015
Source National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

This study will determine the usefulness of pulsing electromagnetic field (PEMF) technology to reverse or reduce the bone loss (osteopenia) that occurs in the forearm after fracture or surgery.


Description:

The long-range goal of this research is to develop a new and supplementary local treatment for osteoporosis to reduce the risk of fracture in susceptible individuals. PEMF is a noninvasive method to magnetically introduce a small amount of electrical current to a specific bone region to stimulate bone formation. PEMFs have been used for many years to treat nonunited fractures and enhance spine fusion healing and have been found to improve bone density in animal models of osteoporosis. Such a noninvasive intervention applied to the hip or spine, which are especially associated with high morbidity and mortality in aging individuals, could have a significant national health care impact.

If effective for the treatment of bone loss, PEMF technology may be effective in treating osteoporosis. The primary objective of this pilot study is to determine the feasibility of using PEMFs to reverse or reduce bone loss that occurs with disuse of the forearm after fracture or surgery and to determine the effect of daily treatment duration on efficacy.

Eighty patients who have recently undergone immobilization after hand surgery or after lower forearm fracture will be enrolled in this study. Participants will be randomized to either the PEMF group or a control group. PEMFs will be administered by means of a magnetic coil transducer placed over the treatment site for 1, 2, or 4 hrs/day for 8 weeks, beginning 6 weeks after the initial injury or surgery. A self-contained, battery-powered PEMF coil transducer already FDA-approved for fracture healing in the forearm will be used. Participants in the control group will receive inactive but otherwise identical units and treatment times. Measurements of bone density will be made using DEXA (dual energy x-ray absorptiometry) and pQCT (peripheral quantitative computer tomography) and compared to baseline. DEXA and pQCT provide planar and cross-sectional x-ray densitometry to determine forearm bone changes. Bone densities (global, cortical, and trabecular), bone cross-sectional structural geometry, and calculated strength index will be measured and compared to baseline values.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date October 2006
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria

- Treatment and immobilization for carpal instability or repair or a lower forearm fracture (Colles' or Smith's) within 6 weeks

- Intact, normal prior skeletal anatomy and function in both arms

Exclusion Criteria

- Previous forearm fracture (either arm), orthopedic procedure, or forearm deformity which might affect forearm bone density

- History of renal disease, liver disease, diabetes, hyperthyroidism, hyperparathyroidism, Cushing's disease, uncontrolled seizures, rheumatoid arthritis, Paget's disease, multiple myeloma, or hypothyroidism

- Implanted cardiac pacemakers or defibrillators

- Pregnant

- Drug therapies within the previous 3 months that could affect bone (e.g., bisphosphonates, estrogen, progesterone, CaF2, calcitonin, steroids, anti-seizure medications)

- Difficulties complying with the protocol due to physical or mental inability, drug or alcohol abuse, psychosis or dementia, imprisonment, or unavailable for follow-up

- History of osteoporosis, as defined by a DEXA T-score of more than 2 standard deviations below normal in the hip, spine, or unaffected forearm

- Prior osteoporotic hip or vertebral fracture

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Device:
Pulsing electromagnetic field (PEMF)


Locations

Country Name City State
United States Institute for Human Performance/Upstate Medical University Syracuse New York

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in bone density and geometry relative to baseline in the PEMF treated forearm during the 24 weeks after immobilization, as compared to the same changes in those receiving sham control treatment
Secondary Changes in chemical markers of bone remodeling in the blood of PEMF treated versus sham control subjects
Secondary bone density and structural changes in the 24 weeks after immobilization, measured by comparing the treated versus the contralateral forearms in subjects receiving PEMF or sham treatment
Secondary influence of age, gender, and other factors
See also
  Status Clinical Trial Phase
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Active, not recruiting NCT05066477 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Bone Mass Among Osteopenic Women N/A
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Not yet recruiting NCT01397838 - Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women Phase 1
Completed NCT01439139 - Bone UltraSonic Scanner (BUSS): Validation Study N/A
Completed NCT01222026 - Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Phase 4
Completed NCT00789425 - Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women Phase 2
Completed NCT01152580 - Melatonin Osteoporosis Prevention Study Phase 1
Completed NCT00463268 - Osteoporosis Prevention With Low Dose Alendronate Phase 3
Completed NCT00655681 - Prevention of Post Operative Bone Loss in Children N/A
Completed NCT00798473 - Zoledronate for Osteopenia in Pediatric Crohn's Phase 3
Active, not recruiting NCT00076050 - Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms Phase 3
Completed NCT00226031 - Optimal Management of Women With Wrist Fractures N/A
Enrolling by invitation NCT04752098 - A Study to Assess Metabolic Bone Disease of Prematurity Using an Acoustic Method N/A
Completed NCT04720833 - Effect of Dried Plum on Bone and Markers of Bone Status in Men N/A
Recruiting NCT05541432 - Finding the Optimal Resistance Training Intensity For Your Bones N/A
Active, not recruiting NCT05405894 - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Completed NCT05457036 - Evaluation of the Effect of Spry Belt Treatment on Bone Turnover Marker Profile N/A
Completed NCT04040010 - The Effects of Bovine Colostrum in Bone Metabolism in Humans N/A
Completed NCT02731820 - Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia N/A